Quantcast
Channel: myelofibrosis – EuropaWire.eu
Browsing latest articles
Browse All 6 View Live

Novartis announced patients with myelofibrosis initially randomized to...

In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with...

View Article



Novartis: CHMP of the European Medicines Agency adopted a positive opinion...

Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib)...

View Article
Browsing latest articles
Browse All 6 View Live




Latest Images